Cargando…
Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer
The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Previous studies demonstrated that the loss of function of CDKN2A is mainly caused by the hypermethylation of CDKN2A gene promoter; however, whether or not it is associated with the incidence of pancrea...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642558/ https://www.ncbi.nlm.nih.gov/pubmed/26338139 http://dx.doi.org/10.1038/srep13563 |
_version_ | 1782400379091156992 |
---|---|
author | Tang, Bo Li, Yang Qi, Guangying Yuan, Shengguang Wang, Zhenran Yu, Shuiping Li, Bo He, Songqing |
author_facet | Tang, Bo Li, Yang Qi, Guangying Yuan, Shengguang Wang, Zhenran Yu, Shuiping Li, Bo He, Songqing |
author_sort | Tang, Bo |
collection | PubMed |
description | The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Previous studies demonstrated that the loss of function of CDKN2A is mainly caused by the hypermethylation of CDKN2A gene promoter; however, whether or not it is associated with the incidence of pancreatic cancer still remains unclear. In this study, we systematically reviewed the association between CDKN2A promoter methylation and pancreatic cancer using meta-analysis methods. The pooled data were analyzed by Review Manager 5.2. Fourteen studies eligible studies, including 418 pancreatic cancer, 155 pancreatic intraepithelial neoplasia (PanINs) and 45 chronic pancreatitis (CP) patients were analyzed. We observed that the frequency of CDKN2A methylation was significantly higher in pancreatic cancer patients than in normal healthy controls, the pooled OR = 17.19, 95% CI = 8.72–33.86, P < 0.00001. The frequency of CDKN2A methylation was also significantly higher in PanINs patients than that in normal individual controls, OR = 12.35, 95% CI = 1.70–89.89, P = 0.01. In addition, CDKN2A methylation was associated with worse survival in pancreatic cancer, HR = 4.46, 95% CI = 1.37–14.53, P = 0.01. The results strongly suggest that CDKN2A methylation is correlated with an increased risk of pancreatic cancer. CDKN2A methylation plays a critical role in pancreatic carcinogenesis and may serve as a prognostic marker. |
format | Online Article Text |
id | pubmed-4642558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46425582015-11-20 Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer Tang, Bo Li, Yang Qi, Guangying Yuan, Shengguang Wang, Zhenran Yu, Shuiping Li, Bo He, Songqing Sci Rep Article The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Previous studies demonstrated that the loss of function of CDKN2A is mainly caused by the hypermethylation of CDKN2A gene promoter; however, whether or not it is associated with the incidence of pancreatic cancer still remains unclear. In this study, we systematically reviewed the association between CDKN2A promoter methylation and pancreatic cancer using meta-analysis methods. The pooled data were analyzed by Review Manager 5.2. Fourteen studies eligible studies, including 418 pancreatic cancer, 155 pancreatic intraepithelial neoplasia (PanINs) and 45 chronic pancreatitis (CP) patients were analyzed. We observed that the frequency of CDKN2A methylation was significantly higher in pancreatic cancer patients than in normal healthy controls, the pooled OR = 17.19, 95% CI = 8.72–33.86, P < 0.00001. The frequency of CDKN2A methylation was also significantly higher in PanINs patients than that in normal individual controls, OR = 12.35, 95% CI = 1.70–89.89, P = 0.01. In addition, CDKN2A methylation was associated with worse survival in pancreatic cancer, HR = 4.46, 95% CI = 1.37–14.53, P = 0.01. The results strongly suggest that CDKN2A methylation is correlated with an increased risk of pancreatic cancer. CDKN2A methylation plays a critical role in pancreatic carcinogenesis and may serve as a prognostic marker. Nature Publishing Group 2015-09-04 /pmc/articles/PMC4642558/ /pubmed/26338139 http://dx.doi.org/10.1038/srep13563 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Tang, Bo Li, Yang Qi, Guangying Yuan, Shengguang Wang, Zhenran Yu, Shuiping Li, Bo He, Songqing Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer |
title | Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer |
title_full | Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer |
title_fullStr | Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer |
title_full_unstemmed | Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer |
title_short | Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer |
title_sort | clinicopathological significance of cdkn2a promoter hypermethylation frequency with pancreatic cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642558/ https://www.ncbi.nlm.nih.gov/pubmed/26338139 http://dx.doi.org/10.1038/srep13563 |
work_keys_str_mv | AT tangbo clinicopathologicalsignificanceofcdkn2apromoterhypermethylationfrequencywithpancreaticcancer AT liyang clinicopathologicalsignificanceofcdkn2apromoterhypermethylationfrequencywithpancreaticcancer AT qiguangying clinicopathologicalsignificanceofcdkn2apromoterhypermethylationfrequencywithpancreaticcancer AT yuanshengguang clinicopathologicalsignificanceofcdkn2apromoterhypermethylationfrequencywithpancreaticcancer AT wangzhenran clinicopathologicalsignificanceofcdkn2apromoterhypermethylationfrequencywithpancreaticcancer AT yushuiping clinicopathologicalsignificanceofcdkn2apromoterhypermethylationfrequencywithpancreaticcancer AT libo clinicopathologicalsignificanceofcdkn2apromoterhypermethylationfrequencywithpancreaticcancer AT hesongqing clinicopathologicalsignificanceofcdkn2apromoterhypermethylationfrequencywithpancreaticcancer |